ArticleBMC oral health2026
Impact of denosumab therapy on periapical healing following root canal treatment: a 10-year retrospective case-control study.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDenosumab is a potent RANKL inhibitor used for osteoporosis, yet its impact on root canal treatment (RCT) outcomes remains less understood compared to bisphosphonates. This study evaluated the periapical healing outcomes of RCT in patients receiving denosumab and identified clinical variables influencing treatment success.
methodsThis retrospective case-control study included 20 patients with osteoporosis receiving denosumab who underwent RCT at a major tertiary hospital between July 2014 and June 2024 (group D), along with 20 age- and sex-matched systemically healthy controls (group C). Among 116 denosumab-treated patients screened, 20 met the strict selection criteria and were enrolled as the study group. Periapical healing was assessed using the Periapical Index (PAI) at a minimum follow-up of 3 months after treatment. Various clinical and radiographic factors, including initial PAI scores and sealer extrusion, were analyzed using logistic regression to determine their impact on healing rates.
resultsThe median follow-up period was 534 (287-956) days for group D and 421 (235-1045) days for group C. The overall periapical healing rates were 75.0.% in the denosumab group and 90.0% in the healthy control group (P = 0.407). Multivariable logistic regression analysis did not identify any statistically significant predictors of healing outcomes. However, higher initial PAI scores (OR = 7.610, P = 0.088) and sealer extrusion (OR = 3.70, P = 0.185) were associated with less favorable outcomes in the multivariable model. Sealer extrusion was significantly associated with healing outcomes in univariate analysis (P = 0.034).
conclusionsWithin the limitations of this study, there was no statistically significant difference in the proportion of healed cases between patients receiving denosumab therapy and healthy controls. These findings suggest that non-surgical root canal treatment may remain a viable tooth-preserving treatment option for patients receiving denosumab therapy. Careful apical control and long-term follow-up may be particularly important in patients presenting with large pre-existing periapical lesions and sealer extrusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.